BD and Ypsomed have begun collaboration to create an optimised, patient-centric autoinjector for high viscosity biologic drugs.
Through this partnership, Ypsomed and BD have pre-assessed and streamlined the integration of BD Neopak XtraFLow, BD's glass prefillable syringe, sigh Ypsomed's YpsoMate 2.25 autoinjector.
The solution will be suitable for biologics that are >15cP, meaning the medical device is capable of dealing with more challenging viscosities, while remaining easy to use.
Neopak XtraFlow is the newest addition to BD's drug delivery portfolio, featuring a shorter 8mm needle.
It also has a thinner wall cannula, improving the flow of therapeutic for subcutaneous delivery.
To accomodate BD's needle, Ypsomed will expand its YpsoMate 2.25 autoinjector platform so it can accomodate the novel syringe format.
Ypsomed's autoinjector device can be administered by removing the cap and pushing on the skin, meaning patients with impaired grip or vision can too administer their medication without needing to attend the clinic.
Ypsomed's Chief Business Officer, Ulrike Bauer, commented: “We are excited to welcome the first pharmaceutical customers to experience the benefits of the BD Neopak XtraFlow Glass Prefillable Syringe with the YpsoMate 2.25 autoinjector,”
“This collaboration underscores our commitment to enhancing patient care through innovative drug delivery solutions.”
President of BD Pharmaceutical Systems, Patrick Jeukenne, added: “Cross-supplier collaborations are vital in today’s pharmaceutical ecosystem,”
“These partnerships can help drive innovation and ensure that systems work by design and over lifecycles, allowing our pharmaceutical partners to get life-saving therapies to patients faster.”
